Synta Pharmaceuticals has dosed the first patient in a Phase I single-agent trial of elesclomol, a potential treatment for acute myeloid leukaemia.
The trial, which will enrol up to 36 patients with relapsed or refractory acute myeloid leukaemia, is being conducted at Princess Margaret Hospital in Toronto, Canada, and at Memorial Sloan-Kettering Cancer Center in New York, US.
Study participants will receive elesclomol sodium once weekly at a starting dose of 200mg/m², with dose-escalation based on safety and tolerability.
The primary endpoints are to characterise the safety and tolerability of elesclomol sodium and establish the pharmacokinetics of elesclomol and its metabolites in the patient population.
Secondary endpoints include evaluating the activity of elesclomol as a monotherapy in the treatment of acute myeloid leukaemia.
Elesclomol is a first-in-class investigational drug candidate that triggers programmed cell death in cancer cells.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData